Rankings
▼
Calendar
KYMR Q4 2024 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
KYMR
Kymera Therapeutics, Inc.
$7B
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$7M
-84.6% YoY
Gross Profit
$7M
100.0% margin
Operating Income
-$81M
-1092.2% margin
Net Income
-$71M
-956.9% margin
EPS (Diluted)
$-0.88
QoQ Revenue Growth
+97.6%
Cash Flow
Operating Cash Flow
-$62M
Free Cash Flow
-$63M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$978M
Total Liabilities
$142M
Stockholders' Equity
$836M
Cash & Equivalents
$120M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$7M
$48M
-84.6%
Gross Profit
$7M
$48M
-84.6%
Operating Income
-$81M
-$19M
-318.2%
Net Income
-$71M
-$14M
-392.4%
← FY 2024
All Quarters
Q1 2025 →